FIELD: chemistry.
SUBSTANCE: invention relates to a heterocyclic compound of formula I
where ring A is selected from 5–6 membered heteroaromatic ring containing one heteroatom selected from nitrogen; ring B is selected from 4–11 membered heterocyclyl containing one or two heteroatoms selected from nitrogen; X1 is selected from CH and N; R1 is selected from C1-6 alkyl; R2 is selected from 5–10 membered heteroaryl containing two heteroatoms selected from nitrogen, where heteroaryl is optionally substituted with one or more substitutes selected from the group consisting of C1-4 alkyl and C3-6 cycloalkyl; R3 and R4 are absent; L is selected from a group consisting of -O-, C1-6 alkylene and 
and alkylene is optionally substituted with one or more substitutes selected from C1-6 alkyl; R5 is selected from C6-12 aryl and 5–10 membered heteroaryl containing one or two heteroatoms selected from nitrogen and sulphur, where each of aryl and heteroaryl is optionally substituted with one or more substitutes selected from the group consisting of halogen, CN, C1-4 alkyl, C1-4 haloalkyl, 5–10-membered heteroaryl containing one or two heteroatoms selected from nitrogen, oxygen and sulfur, and -OR31, where heteroaryl is optionally substituted with one or more substitutes selected from a group consisting of halogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 alkoxy, C3-6 cycloalkyl and C3-6 cycloalkoxy; each of R23a and R23b is independently H; R31 is independently selected from C1-6 alkyl and C3-8 cycloalkyl; m is equal to 0; n is equal to 0; and t is 0 or 1; provided that if ring B is a piperazine ring and X1 is CH, R2 is not 4-CF3-pyridin-2-yl or 4-CN-pyridin-2-yl, as well as to methods for its preparation, a pharmaceutical composition and use in preparing a drug for preventing or treating a disease or condition associated with RET activity.
EFFECT: obtaining novel compounds which can be used in preparing a drug for preventing or treating a disease or condition associated with RET activity, such as cancer, or a tumour, or irritable bowel syndrome.
46 cl, 5 tbl, 4 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| SUBSTITUTED 1,2-DIHYDRO-3H-PYRAZOLO[3,4-D]PYRIMIDIN-3-ONES | 2019 |
|
RU2812726C2 |
| INHIBITOR CONTAINING BICYCLIC DERIVATIVE, METHOD OF PREPARATION AND USE THEREOF | 2020 |
|
RU2820948C2 |
| 1,5-NAPHTHRIDINE DERIVATIVES AND MELK INHIBITORS CONTAINING THEM | 2012 |
|
RU2645339C1 |
| DERIVATIVE OF PYRIMIDINE AND A FIVE-MEMBERED NITROGEN-CONTAINING HETEROCYCLE, METHOD FOR PRODUCTION AND MEDICAL APPLICATIONS THEREOF | 2019 |
|
RU2775229C1 |
| BENZAMIDE COMPOUNDS | 2019 |
|
RU2801647C2 |
| OXASPIRO DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINES | 2016 |
|
RU2733373C2 |
| INFLUENZA VIRUS REPLICATION INHIBITORS, METHODS OF APPLICATION AND USING | 2016 |
|
RU2737190C2 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2734390C2 |
| ANILIDES OF AMINO ACIDS AS LOW-MOLECULAR MODULATORS IL-17 | 2019 |
|
RU2815505C2 |
| HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | 2012 |
|
RU2648997C2 |
